We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+28.55%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$465M
AUM Growth
+$35.8M
Cap. Flow
-$14.7M
Cap. Flow %
-3.15%
Top 10 Hldgs %
71.37%
Holding
58
New
2
Increased
2
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
PRME icon
Prime Medicine
PRME
+$8.5M
2
IMTX icon
Immatics
IMTX
+$5.12M
3
ZYME icon
Zymeworks
ZYME
+$4.57M
4
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$4.4M

Top Sells

Rank Stock Value
1
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$21.3M
2
JYAC
Jiya Acquisition Corp. Class A Common Stock
JYAC
+$5.05M
3
VRNA
Verona Pharma
VRNA
+$3.25M
4
BLSA
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
+$3.01M
5
ACLX
Arcellx
ACLX
+$2.44M

Sector Composition

Rank Sector Weight
1 Healthcare 99.94%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRS
26
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$3.16M 0.68%
881,450
– –
ALXO icon
27
ALX Oncology
ALXO
$290M
$2.96M 0.64%
262,786
– –
IGMS
28
DELISTED
IGM Biosciences
IGMS
$2.63M 0.57%
154,664
– –
IOBT
29
DELISTED
IO Biotech
IOBT
$2.32M 0.5%
1,008,437
– –
AMYT
30
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$2.22M 0.48%
304,715
– –
ALBO
31
DELISTED
Albireo Pharma Inc
ALBO
$2.16M 0.47%
100,000
– –
TERN
32
DELISTED
Terns Pharmaceuticals
TERN
$2.06M 0.44%
202,348
-86,720
-30% -$577K
EYPT icon
33
EyePoint Inc
EYPT
$1.2B
$1.68M 0.36%
480,000
– –
DBTX
34
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$1.64M 0.35%
801,629
– –
ALLK
35
DELISTED
Allakos
ALLK
$1.45M 0.31%
172,089
– –
BOLT icon
36
Bolt Biotherapeutics
BOLT
$7.78M
$1.36M 0.29%
52,458
– –
TIL icon
37
Instil Bio
TIL
$50.3M
$1.13M 0.24%
89,414
– –
VTVT icon
38
vTv Therapeutics
VTVT
$139M
$1.08M 0.23%
40,888
– –
VIRX
39
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.01M 0.22%
689,709
– –
ELEV
40
DELISTED
Elevation Oncology
ELEV
$789K 0.17%
830,565
– –
EQ icon
41
Equillium
EQ
$133M
$652K 0.14%
615,541
– –
SWTX
42
DELISTED
SpringWorks Therapeutics
SWTX
$578K 0.12%
22,204
– –
KALA icon
43
KALA BIO
KALA
$14.5M
$459K 0.1%
240
– –
KLRS
44
Kalaris Therapeutics
KLRS
$96.8M
$422K 0.09%
3,580
– –
SYRE icon
45
Spyre Therapeutics
SYRE
$9.25B
$398K 0.09%
35,349
– –
SNCE
46
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$374K 0.08%
45,000
– –
ATXS
47
DELISTED
Astria Therapeutics
ATXS
$372K 0.08%
25,000
– –
BCEL
48
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$318K 0.07%
396,835
– –
NVAX icon
49
CALL
Novavax
NVAX
$1.31B
$241K 0.05%
23,400
– –
NVAX icon
50
Novavax
NVAX
$1.31B
$218K 0.05%
21,244
– –
1
2
3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q4 2022 Portfolio in Review

As of Q4 2022, Samsara BioCapital held 58 positions worth $465M, up 8.3% from $429M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Samsara BioCapital withdrew a net $14.7M in Q4 2022, closing 3 positions and reducing 4 holdings. Its most notable exit was Forma Therapeutics Holdings, Inc. Common Stock, an estimated $21.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Financials.

Against the trend, Samsara BioCapital opened a new position in Prime Medicine worth $8.74M.

  • Samsara BioCapital's largest Q4 2022 buy was Prime Medicine: 470,304 shares worth $8.74M.
  • Samsara BioCapital added most to Zymeworks in Q4 2022, an estimated $4.57M increase.
  • Samsara BioCapital's biggest Q4 2022 reduction was Verona Pharma, cutting an estimated $3.25M.
  • Samsara BioCapital fully exited Forma Therapeutics Holdings, Inc. Common Stock in Q4 2022, selling an estimated $21.3M.
  • Samsara BioCapital's ten largest holdings make up 71% of its $465M portfolio in Q4 2022.
  • Samsara BioCapital opened 2 new positions and closed 3 in Q4 2022.
  • Samsara BioCapital's portfolio value rose 8.3% quarter-over-quarter to $465M.

Based on Samsara BioCapital's 13F filing for Q4 2022, filed 14 Feb 2023.